No data to show
XHKG
3681
Market cap157mUSD
Apr 11, Last price
1.13HKD
1D
0.00%
1Q
14.14%
IPO
-75.33%
Name
SinoMab BioScience Ltd
Chart & Performance
P/E
—
P/S
841.45
EPS
—
Div Yield, %
—
Shrs. gr., 5y
0.23%
Rev. gr., 5y
-1.60%
Revenues
2m
+48.42%
Net income
-185m
L-23.85%
CFO
-131m
L-2.28%
Earnings
Jun 13, 2025
Profile
SinoMab BioScience Limited, a biopharmaceutical company, engages in the research, development, manufacture, and commercialization of therapeutics for the treatment of immunological diseases primarily monoclonal antibody (mAb)-based biologics. Its flagship product is SM03, a first-in-target anti-CD22 mAb, which is in Phase III clinical trial for the treatment of rheumatoid arthritis (RA), as well as in various clinical stages for other immunological diseases, such as systemic lupus erythematosus (SLE), Sjogren's syndrome (SS), and non-Hodgkin's lymphoma (NHL). The company also focuses on developing SN1011, a Bruton's tyrosine kinase inhibitor, which is in Phase II clinical trial for the treatment of pemphigus, as well as in phase 1 clinical trial to treat multiple sclerosis, SLE, and NMOSD. Its products under the preclinical stage comprise SM17 for the treatment of asthma, atopic dermatitis, and idiopathic pulmonary fibrosis; SM06 to treat RA, SLE, NMOSD, and SS; SM09 for the treatment of NHL and RA; and TNF2 for the treatment of autoimmune diseases. The company operates in Mainland China, the Cayman Islands, and Hong Kong. SinoMab BioScience Limited was incorporated in 2001 and is headquartered in Pak Shek Kok, Hong Kong.
Valuation
Title CNY in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|
| 2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | |
| Income | ||||||||
Revenues | 2,026 48.42% | 1,365 -66.15% | 4,032 -84.87% | |||||
Cost of revenue | 163,952 | 233,967 | 262,959 | |||||
Unusual Expense (Income) | ||||||||
NOPBT | (161,926) | (232,602) | (258,927) | |||||
NOPBT Margin | ||||||||
Operating Taxes | ||||||||
Tax Rate | ||||||||
NOPAT | (161,926) | (232,602) | (258,927) | |||||
Net income | (185,141) -23.85% | (243,111) -14.45% | (284,158) -1.40% | |||||
Dividends | ||||||||
Dividend yield | ||||||||
Proceeds from repurchase of equity | 10,038 | 46,085 | ||||||
BB yield | ||||||||
| Debt | ||||||||
Debt current | 125,580 | 71,251 | 45,801 | |||||
Long-term debt | 419,676 | 438,970 | 326,762 | |||||
Deferred revenue | ||||||||
Other long-term liabilities | (238,358) | |||||||
Net debt | 438,378 | 275,564 | (49,822) | |||||
| Cash flow | ||||||||
Cash from operating activities | (130,801) | (133,847) | (300,538) | |||||
CAPEX | (103,338) | (112,751) | ||||||
Cash from investing activities | (94,482) | (96,921) | (81,358) | |||||
Cash from financing activities | 73,268 | 82,267 | 102,285 | |||||
FCF | (176,415) | (283,559) | (388,537) | |||||
| Balance | ||||||||
Cash | 106,878 | 234,657 | 422,385 | |||||
Long term investments | ||||||||
Excess cash | 106,777 | 234,589 | 422,183 | |||||
Stockholders' equity | 192,911 | 1,785,813 | 509,575 | |||||
Invested Capital | 568,405 | 511,802 | 444,006 | |||||
ROIC | ||||||||
ROCE | ||||||||
| EV | ||||||||
Common stock shares outstanding | 1,073,650 | 1,018,116 | 991,956 | |||||
Price | ||||||||
Market cap | ||||||||
EV | ||||||||
EBITDA | (161,926) | (196,538) | (231,896) | |||||
EV/EBITDA | ||||||||
Interest | 6,584 | |||||||
Interest/NOPBT | ||||||||